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CHAPTER I 
INTRODUCTION 
Hesse, in 1927 (l) , "was perhaps the first to show that Flexner-
Jobling rat carcinoma could be transmitted by the ascitic fluid that 
developed during the growth of the tumor. Koch (2) , one year later, con­
firmed this finding and also showed that the tumor developed better when 
injected intraperitoneally, and that the number of tumor cells in the 
ascitic fluid increased with time. In 1932, Lowenthal and Jahn (3), Koch's 
collaborators, obtained on injection of Ehrlich mouse carcinoma, an 
ascites-producing tumor instead of the usual solid tumor. This ascites 
tumor could be transplanted successfully through intraperitoneal injection 
of the ascitic fluid. Thus Lowenthal and Jahn (3) established a new line 
of the Ehrlich carcinoma, which they called the ascites tumor. This 
ascites tumor found wide use in experimental studies in Germany soon after 
it was discovered (4, 5, 6, 7), and in recent years it has been widely 
employed for other studies. Lettre (5), for example, used it to study 
chemotherapeutic agents, Klein and co-workers (8) studied its chemical 
composition, and Warburg and Hiepler (6) studied its metabolism. Hauschka 
and Levan (9) and Hauschka (10) recognized the extraordinary significance 
of this ascites tumor as a convenient material for the study of chromo­
somes, cell morphology and tumor transplantation immunity. 
In 1948, Klein and co-workers (11) converted a solid line of 
Ehrlich mouse carcinoma into the ascitic form and named it the 
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tetraploid line of Ehrlich mouse ascites carcinoma. Since then a wide 
variety" of transplantable tumors have been converted into the ascitic 
form. Interesting types of ascites tumor have been reported by 
Craigie (12), Makino (13), Tanaka (lU), Takeda (15), SheIton (l6), 
Isaka (17), Bather (18), Williams (19), and Fekete and Griffen (20). 
The general characteristics of the Slirlich mouse ascites tumor 
have been studied by Klein and co-workers (21). After an animal is 
given an intraperitoneal injection of the tumor fluid, it develops a 
progressive ascites. The time required for the ascites to become 
manifest varies inversely with the number of cells in the inoculum. 
With the usual dose of 0.1 ml of the ishole fluid (approximately 
9 X 10̂  cells), it takes 6 to 8 days for the ascites to become grossly 
noticeable. With lower doses it may take as long as twenty days 
before any ascites is recognizable, and if the dose is much lower, 
ascites may not be produced at all,' Instead, a solid implantation and 
growth occur on the omentum or some other part of the peritoneal 
membrane (21). 
The morphology of the Ehrlich ascites tumor cells has been 
studied by phase microscopy, ordinary light microscopy (22) and 
electron microscopy (23). Under the phase microscope, the tumor cells 
display fine hair-like pseudopodia averaging about 1 micron in length, 
a well defined nucleus with irregularly clumped chromatin, and the 
cytoplasm. The cytoplasm contains two readily distinguishable 
components s 1) the mitochondria that appear as short dark rodlets and 
2) sees brilliantly refractile globules that contain large amounts of 
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lipxd (23). In 1958, Hirono and Iwao (2U) reported that the living 
Ehrlich ascites tumor cells when observed in hanging drop preparations, 
after incubation at 37° G for 1 hour, display ameboid movement and 
pseudopod formation. The average measured motility of the cells was 
about 0.9 microns per minute. 
Studies mth stained preparations (2$, 26, 27) have shown that 
the nucleus contains several prominent nucleoli. Inside many of these 
nucleoli there are fine vacuoles. In addition to the nucleoli and the 
chromatin, the nucleus also contains finely granular parachromatin (26) 
which stains acidophilic. In old tumors, the chromatin and the para­
chromatin of an occasional cell are margins ted and 1 or more acido­
philic bodies are formed. The nature of these bodies is made clear 
by the use of toluidine-blue-molybdate stain (27), which stains the 
desoxynucleoprotein content of the cell» By this method the desoxy-
nucleoprotein of the parachromatin stains purple and that of the 
nucleolus green. Many of the nucleoli contain metachromatic 
ribonucleoprotein bodies or nucleolini (28), which appear to corre­
spond to the vacuoles seen in other preparations. Under the microscope 
it can be seen that the large inclusions consist of a homogeneous 
green-staining center, derived from the nucleolus, covered by purple 
parachromatin granules. In degenerating cells smaller inclusions 
appear to be entirely formed by condensation of the parachromtin, A 
study of the old ascites tumor cells reveals that these cells eventu­
ally degenerate and disintegrate, going through the conventionally 
recognized processes of pyknosis, karyorrhexis and karyolysis, after 
which the fragments are digested by the macrophages. 
The cytoplasm of the Ehrlich ascites tiimor cell contains 3 types 
of lipid particles (25). Seme of these particles are large droplets 
which stain red with Nile-blue sulfate. These are especially predom­
inant in older degenerating cells and cells that are infected with 
viruses (29, 30, 31). The second type of lipid droplets consists of 
an amorphous, acidic, Schiff-periodic acid-positive material found 
chiefly in the perinuclear zone of the cytoplasm. These granules 
consist mainly of phospholipids (32), and are found in the region 
where the golgi apparatus is located (22). Like the golgi apparatus, 
these phospholipid granules also are stained by the Kolatchew golgi 
apparatus staining technic (33)» The third type of these lipid 
particles in the cell consists of the mitochondria. These are more 
regular in shape and are distributed more evenly than the former 
particles in the cytoplasm (34). In the degenerating cells of the old 
tumors, neither the mitochondria nor the golgi apparatus are altered 
significantly except during the final stage of disintegration of the 
cell. 
Studies of the cellular component of the ascites at different 
phases of growth of the tumor, have shown that the cells consist 
mainly of tumor cells, but red blood cells and inflammatory cells are 
also present. The relative proportion of the red cells varies. Some 
fluids are grossly hemorrhagic while others are relatively clear. The 
red blood cells present in the fluid display poikilocyfcosis and 
hypochranesia (35). Fair proportion of these are also nucleated. The 
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proportxon of inflammatory cells varies with the individual animal and 
with the age of the tumor. Generally in early stages of growth the 
percentage of non-tumor cells has been found to be inversely related 
to the number of tumor cells in the inoculum (21), A variation in the 
physiological ages of the inocula has little or no effect on cell 
count. The latent period (l,e., the period preceding the actual 
increase in the cell count) is prolonged when older inocula are used, 
Klein and co-workers (21) investigated the tumor growth using 3-j 6-, 
and l6-day-old fluid as inocula. They collected the fluid after a 
definite period, rinsed the peritoneal cavity twice with saline and 
determined the total volume of fluid and number of cells per animal. 
Thus they were able to determine the various phases of growth of the 
Ehrlich mouse ascites tumor. These phases ares l) the latent phase, 
2) the phase of logarithmic growth, 3) the stationary phase in which 
more fluid than cells is formed and It) the regression phase during which 
the dead cells predominate. They reported that with inocula of various 
ages, the growth curves were more or less parallel, and the difference 
between regression phases was not at all marked. On the basis of these 
observations, Klein concluded that the physiological age of the inoculum 
has no discernible effect on the proliferation of the tumor cells. 
The tumor cell population consists of both living and dead tumor 
cells. They can be differentiated by staining a wet smear of fresh 
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fluid with nigrosin (36). The living cells take up the vital stain 
and are consequently stained black. The dead cells remain unstained. 
The tumor cells have been counted in different ways by different 
workers. Hemocytometric counting chambers have been employed most 
successfully and conveniently (21), An ascitocrit, a modification of 
a hematocrit, is the next most widely employed tool for this purpose 
(37)» Klein and co-workers using the hemocytometer have reported the 
tumor cell count of the ascitic fluid at different stages of growth of 
the tumor (21), These workers found that after a latent period of 
about ii.8 hours, the cell count started rising more or less logarith­
mically till it reached the peak on or about the 9th day. The 
inflammatory cells were a predominant feature of the ascitic fluid 
during the latent period. From the 9th to the 11th day the cell 
count was relatively stationary. Since the amount of fluid produced 
was very high at this stage, "Uie cells were diluted and the count was 
low per unit volume (about 1 x 10® cells per ml) as compared to the 
cell count at the peak of the growth curve (2-3 x 10® per ml). After 
the 11th day the phase of regression ensued where the proportion of 
dead cells increased (21). 
The fluid component of the ascites increased progressively as the 
infection proceeded. Tlïhen 0.1 ml of the whole fluid was used as 
inoculum, the fluid varied from 5 to 8 ml on the 6th day to 12 to 
l5 ml on the 16th day* The protein content of this ascitic fluid was 
lower than that of serum from tumor-bearing mice (3.1 gm % in fluid 
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and ii.9 gm ̂  in serum). The serum from normal mice contains 6,7 gm of 
protein per 100 ml. The albumin content of the ascitic fluid nvas 
especially low (0,9 gm %). The concentration of alpha- and gamma­
globulins was also lower when coiqpared with the serum (38). However, 
the beta-globulin level was higher (1,1 gm %) in the ascitic fluid than 
in the sera of mice bearing the tumor (0.6 gm̂ ). The properdin titer 
of ascitic fluid was never more than ii,0 units per ml, whereas the serum 
of tumor-bearing mice contained 10 to hO units of properdin per ml. 
The most obvious effect of tumor growth on the host is the pro­
duction of ascites» This ascites formation leads to respiratory 
embarrassment5 toxemia, hepatic dysfunction, renal insufficiency and 
finally death. In 1933s Putnoky (35) followed the changes in the 
peripheral blood in rats after injecting the tumor intra per i toneally, 
He noticed a rise in polymorphonuclear count accompanied by a simultan­
eous fall in the number of the lymphocytes. Monocytes and eosinophils 
also decreased in number. The platelet count showed a transient rise. 
Anemia was a marked feature and the red blood cells displayed aniso-
eytosis, poikilocytosis and polychromatophilia. Nucleated red cells 
and reticulocytes were abundant. Coagulability of the blood was 
unaffected, Putnoky (35) also reported that these changes were 
reproducible with autolysates, emulsions and ethereal extracts of 
necrotic tumor cells. 
The literature on tumor immunity is so extensive that even as 
early as 1916, lyzzer (39) stated that "It is quite impossible to 
present within reasonable space, a comprehensive review of all 
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investigations done on tumor-immunity," A second review by Waglom in 
1929 contained over six hundred references (ij.0). 
Specific immunity to transplantable tumors is the reaction of an 
organism to a foreign cell. Bie degree of this reaction or immunity 
depends on the foreign-ness of the tumor cells. Much work has 
been done in this field, Caspari in 1929 (l&l)̂  introduced the 
concept of "necrohormones" which he thought were produced as a 
result of degeneration of the tumor and caused the development 
of a general immunity. Lumsden, (1̂ 2) in 1931, went to the extent 
of saying that "There is no antibody whose existence is more 
proved than that of these anti-malignant-cell antibodies." He 
described five types of antibodies against tumor cells; 1) anti-
species antibody, 2) homologous cytotoxins, 3) normal hetero-
cytotoxins, k) autocytotoxins, and 5) cytotoxins for malignant 
cells present only in animals with tumors. In 1937, however, 
Phelps (ii.3) showed that the antibodies of the so-called anti-
sera of Lumsden had no specific action on the cancer cells and 
were not peculiar to the malignant cells. He described them 
as isoantibodies in response to foreign though homologous cells 
that were injected. 
Gprer (iiU, hS) introduced the idea that genes were respon­
sible for isoantigenic differences and showed that certain important 
isoantigens were shared by mouse erythrocytes, normal fixed tissues 
and the tumor cells, Hauschka (10) postulated that successful trans­
plantation of a graft depended on the simultaneous presence of dominant 
genes, in the graft as well as in the host. He also said that this was 
true for normal as well as for neoplastic tissues. If a tumor graft 
carries one or more dominant loci functioning in the direction of 
elaboration of cellular antigens, and the host has inactive or immuno­
logically different alleles of these genes, the implant evokes 
antibodies against itself and usually regresses. If on the other hand 
the pertinent antigenic alleles are dominant in both the tumor and the 
host, no immune reaction ensues, and the tumor transplant continues to 
grow. 
It has been shown that most of the malignant cells contain 
various antigens (I4.6, klf U8, h9s 50), some of which are common to 
normal tissues. Various reports have appeared I'egarding the demon­
stration of specific neutralizing and/or agglutinating antibodies 
against different tumors. Neutralizing antibodies against Rous Sarcoma 
were described in the sera of recovered chickens by Kabat and co­
workers (5l). Kidd demonstrated neutralizing antibodies against Brown-
Pearce carcinoma (52) and Shope papilloma (53). Bennison (5%) and 
Imagawa (55) demonstrated antibodies against Bittner milk agent for 
mammary carcinoma. Flax (80) and Horn (81) reported the successful 
neutralization of the carcinogenic property of Ehrlich ascites tumor 
cells by incubating them with rabbit antiserum. Flax, however, could 
not demonstrate any in vitro neutralization without the addition of 
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guinea pig complement to the antiserum. The gamma-globulin fraction of 
this antiserum ivhen combined with guinea pig complement could also 
neutralize the tumor (80), Treatment of this gamma-globulin-complement 
complex at $6^ G for 30 min destroyed its neutralizing power, Horn 
(8l) was able to demonstrate neutralization of the tumor without the 
addition of complement. Flax also observed that the average survival 
period of the tumor-bearing mice was almost doubled when they were 
treated with the antiserum or gamma-globulin fraction of this antiserum 
after challenge. Recently Sukhorukikh (82, 83, 8î ) demonstrated a 
definite cytotoxic effect of agglutinating antiserum on the tumor cells. 
The same author (83) also demonstrated the inhibition of mitotic activ­
ity of the tumor cells after incubation with the agglutinating anti­
serum, Normal rabbit serum and antisera prepared against liver and 
spleen from normal mice, failed to produce this inhibition. 
Snail and his associates (56) showed that dead tissue or tissue 
products could be used as active immunizing agents against trans­
plantable tumors, Tizzoni and co-workers (57)5 in 1930, used malignant 
cells killed with formalin and phenol to immunize mice against an 
adeno-carcinom (8281). Bittman and Goldfeder in 1929 (58) prepared 
antisera against Shrlich mouse carcinoma and demonstrated that mice 
injected with this antiserum before tumor transplant were not protected, 
while if "tJie antiserum was given after the tumor, there was a slight 
inhibitory effect. Gostero in 1930 (59) made attempts to immunize mice 
against Ehrlich mouse carcinoma by injecting intravenously autolysates 
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of muscles from cancerous mice but was not successful. Schabad in 19.39 
(60) reported that addition of splenic tissue from normal mice inhib­
ited the growth of Ehrlich mouse carcinoma, whereas spleen from 
cancerous mice lacked this property. Lund (61) in 19̂ 8, was successful 
in immunizing rats against ïoshida sarcoma by intracecal injection of 
tumor cells. Recently Donaldson and Mitchell (62) immunized 90% of 
mice against Ehrlich ascites tumor by using tumor cells killed with 
x-rays5 and Donaldson and North (63) immunized mice against this tumor 
by using tumor cells killed with nitrogen-mustard. 
Before closing this chapter, the subject of non-specific immunity 
to tumors will be briefly reviewed. It is known that administration of 
neutral polysaccharides of diverse plant, animal and microbial origins 
to experimental animals profoundly affects the resistance to bacterial 
infection and growth of tumor transplants. Large doses of zymosan or 
bacterial polysaccharides transiently decrease the resistance of mice 
to gram-negative bacterial infection (6L, 65) and cause increased 
growth and lethality of Sarcoma 180 in mice (66), human epidermoid 
carcinoma in rats (67), and human intestinal adenocarcinoma in rats 
(68). Conversely, small doses of polysaccharides increase the 
resistance of mice to infection (65, 69̂  70, 71, 72, 73) and increase 
the rejection of Sarcoma 180 (66, 7k) and Sarcoma 37 in mice. Lack of 
cross-antigenicity between zymosan and these pathogens indicates that 
these effects are the result of an initial depression followed by 
stimulation of non-specific host defense mechanisms. The effect of 
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polysaccharides on susceptibility to infection and tumor growth varies 
inversely as its effect on serum properdin levels (70, 71, 7U), 
suggesting that properdin, or another defense mechanism which fluc­
tuates simultaneously with properdin, may be involved in tumor rejection 
mechanism* Kidd (76), Ainis (77) and Herbut (78) have demonstrated in 
guinea pig serum a non-specific humoral factor, probably different from 
complement and properdin, which inhibits the growth of a rat 
lymphosarcoma. 
To summarize the issue of immunity and cancer, Southam (79) may be 
quoteds "In spite of the complete absence of proof, the existence of 
so many suggestive bits of clinical and experimental data sustains the 
working hypothesis that cancer is not a wholly autonomous growth but 
may be susceptible to restraint by the host mechanisms," 
CHAPTER II 
STATEMENT OF PROBLEM 
From the review of the literature, it appeared reasonable to assume 
that tumor transplants are influenced by the host defense mechanisms 
which could be modified by specific and non-specific means. With this 
assumption in mind, it was decided to study: 1) active immunization of 
mice by the use of Ehrlich ascites tumor cells treated with different 
physical and chemical agents, 2) passive immunization by the use of 
Ehrlich-ascites-tumor-cell-agglutinating rabbit antiserum, and 3) non­
specific immunization induced by Bordetella pertussis cells, zymosan, 
Escherichia coli endotoxin and Freund's incomplete Bacto-adjuvant. 
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CHAPTER III 
MATERIALS AND METHODS 
MATERIALS: 
Tumor? A line of the ascitic form of Ehrlich ascites tumor was 
obtained from Dr. P. C. Rajam of the University of Michigan on May 9, 
1959, and ms maintained in the Stella Duncan Laboratory, Montana State 
University, through weekly intraperitoneal transfers in female mice. 
Mice; In most of the experiments, 5- to 7-week old mice of the CFW 
(Swiss Webster) strain purchased from Carworth Farms, New City, New York, 
were used. In some experiments, the strain of white mice kept at the 
Rocky Mountain Laboratory, Hamilton, Montana, was used. 
Rabbits ; Male rabbits weighing between 4 and 6 pounds were used for 
preparing the antiserum. These rabbits were of undetermined strain, and 
were purchased from the Dry's Rabbit Farm, Veradale, Washington. 
Physiological saline ; 0.85% sodium chloride in distilled water is 
referred to as physiological saline. 
FormalinÎ 36.3̂  formalin solution, lot No. 545228, obtained from 
the Fisher Scientific Company was used. 
Phenol; Crystalline phenol, lot No. 90851, obtained from the J. T. 
Baker Company was used. 
Merthiolate: 1:1,000 merthiolate (thimerosal), lot No. 6133-738850, 
containing 0.1$ monoethanolamine and obtained from Eli Lilly Company was 
used. 
-14-
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Freund's Adjuvant; 10,0 ml ampoules of Freund's Incomplete Bacto-
adjuvant, lot No, 0639-60, control hh3̂ 05 purchased from the Difco 
Laboratories were used. 
Bordetella pertussis Cells; Cells were grown in the liquid medium 
of Verwey at al. (88), and were killed by the addition of 0.01% 
merthiolate. These merthiolate-killed cells were kept in a suspension 
containing 700 billion cells per ml in saline with 0.01% merthiolate, 
Escherichia coli Lipopolysaccharideî Batch No. L583-362, 10-1, 
obtained from Merck Sharp and Dohme Company through the courtesy of 
Dr. 0. Ganley was used. 
Zymosans Lot No. 71313, obtained from the Fleischmann Laboratories, 
Betts Avenue, Stanford, Connecticut, was used. 
METHODSs 
Collection of Fluids From the growth curves obtained in mice 
inoculated with 0.2 ml of Shrlich mouse ascites tumor fluid, it can be 
said that the maximum number of cells (about 1 x 10̂  per ml) is 
obtained around the 8th day after the inoculation. At this stage, the 
number of dead tumor cells and inflammatory cells is at its lowest 
point (21), For these reasons, the tumor fluid for all experimental 
purposes (unless stated otherwise) was collected by tapping the mice 
on the 8th day after the tumor inoculation. The tapping was done with 
an 18 gauge sterile needle inserted in the region of the left iliac 
fossa, !Hie fluid was allowed to flow out into a test tube. On many 
occasions the needle was removed and the fluid allowed to flow out of 
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the puncture wound. The fluid thus obtained was stored in the refrig­
erator or used immediately. In no case was a sample of fluid stored 
for more than 18 hours, as it has been shown that after 30 hours in the 
refrigerator, most of the cells are dead. 
Washing the Tumor Cells? Tumor cells were obtained reasonably 
free from fibrin clots and necrotic debris by centrifuging the whole 
fluid at a rate of 2,000 rpm for 5 m in at 6° G in a model S-8 Servall 
centrifuge. The turbid supernatant was pipetted off, mixed with an 
equal volume of physiological saline, and centrifuged at 5,000 rpm for 
5 min. The sedimented cells were re suspended in saline and mixed 
thoroughly. Then they were spun down again. This was repeated $ times 
or until the cells ceased to form sticky clumps (85). Cells properly 
washed went into suspension rather easily. 
Standardization of Cell Suspensions? Serial tenfold dilutions of 
the cells were made in saline by adding 0.5 ml of suspension to ml 
of saline. The third and fourth dilutions were counted in a 
Heubauer-type Hemocytometer counting chamber. The cell content was 
calculated as followss 
Total cell count in the four chambers x 10 - No. of cells 
It ~ ~ per cu mm 
Suspensions for Challenge ; The fluid for this purpose was usually 
obtained from a female CFW mouse that had received the tumor 8 to 10 
days previously. Dilutions were made in saline to give a final cell 
count of 20,000 per ml. Four to six thousand cells (0,2 to 0,3 ml) 
were injected intraperitoneally. The suspension was injected within 
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half an hour after making the dilutions in order to avoid any serious 
injurious effect of saline on the tumor cells. This dosage of ij.,000 
to 6,000 cells was chosen because it was shown that the ascites became 
manifest by the 20th day after this challenge. With lower doses the 
incidence of the tumor in ascitic form was lower and ascites became 
apparent only after a longer period of time (3̂  to l+O days). 
Treatment with formalinî Cells were separated from 5.0 ml of 
fluid and washed 3 times with saline. Then they were re suspended in 
saline to a final concentration of 5 x 10̂  cells per ml. To ii,0 ml of 
this suspension contained in a 25 ml pyrex glass beaker were added 
O.Oli ml of formalin and l6.0 ml saline. The suspension was thoroughly 
mixed and allowed to stand at room temperature for 2 hours with 
occasional manual agitation, and then kept in the refrigerator for 16 
hours. At the end of this period this cell suspension was used to 
vaccinate mice. Freshly formalinized cells were used for each 
vaccination. 
Treatment with phenol: Saline-washed cell suspensions containing 
5 X 10̂  cells per ml were made as for the preparation of formalinized 
cells. The cells from 20,0 ml of this suspension were separated by 
centrif ligation and re suspended in 20.0 ml of 0.8# phenol in a 50 ml 
pyrex glass beaker. This suspension was thoroughly mixed and allowed 
to stand at room temperature for 1 hour and then in the refrigerator 
for 18 hours. At the end of this time, the cells were separated and 
washed twice with saline to remove excess phenol, and then resuspended 
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in 20.0 ml of saline. This suspension was used to vaccinate mice. 
Freshly treated cells were used for each vaccination. 
Treatment with merthiolate; A washed cell suspension containing 
5 X 10̂  cells per ml was prepared as above. Three ml of this suspension 
were added to a 25 ml beaker containing 5,0 ml of saline and 2,0 ml of 
1*1000 merthiolate. This su&pension was allowed to stand at room 
temperature for 2 hours with frequent shaking, and then kept in the 
refrigerator for 16 hours. At the end of this period, the suspension 
was used to vaccinate mice. Freshly prepared merthiolate-treated cells 
were used for each vaccination. 
Preparation of disrupted cells? Approximately ij. gm of No, 12 
Cataphote glass beads and 5.0 ml of a saline suspension of cells con­
taining 5 X 107 cells per ml were placed in a Mickle reed and shaken 
in a Mickle disintegrator for li min. This was repeated U times with 5 
to 10 min intervals between each treatment. Samples were examined 
under the microscope to determine the degree of disruption. If less 
than 80% of the cells were disrupted, the mixture was shaken once more 
for ii min. Then the glass beads were allowed to settle and the broken 
cell suspension was pipetted off, When only cell extract was desired, 
this suspension kept at 6° C was centrifuged at 8,000 rpm for 10 min 
and the supernatant was decanted and again similarly centrifuged to 
remove the cell debris. 
Irradiation with ultraviolet light? A G15-8T model ultraviolet 
lamp (2,537 A) purchased from the General Electric Company was used. 
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No exact measure of the ultraviolet light intensity emitted from this 
lamp was made and for this reason it is not possible to specify in 
exact terms the dose of ultraviolet light administered to the tumor 
cells. To vary the dose, only the time of exposure was varied. The 
procedure used was as follows; 
Two and one-half ml of the tumor fluid were diluted ten times by 
adding 22.5 ml saline. Ten ml of this diluted fluid were placed in a 
glass petri dish 9.0 cm in diameter. After allowing the lanp to warm 
up for 15 min, the dish containing the fluid was placed on a platform 
at a distance of 30 cm below the center of the laiip. This platform was 
mechanically rocked to keep the fluid under constant agitation. 
Samples of fluid were irradiated for 10 and 15 min̂  and then injected 
into mice within 15 min after irradiation. The energy emitted by the 
lamp under the specified conditions was approacimately 32.3 ergs/ram2/sec 
(86)* ThereforeJ the energy derived from 10 min irradiation was approx­
imately 10 X 60 X 32.3 or 19,380 ergs/mm̂ j and that from 15 min 
irradiation, 20,070 ergs/mm̂ . 
Immunization of rabbits ; Six rabbits were divided into 2 groups 
of 3 eachj group I received intact tumor cells and group II received 
disrupted cells. Thirty ml of blood was collected from each rabbit 
before starting the immunizing injections. Then they were given 
subcutaneous injections of 2,0 ml of the immunizing material (washed 
cells in saline with 9 x 10̂  cells per ml or 2,0 ml of the broken-cell 
suspension). These injections were given at three-day intervals for a 
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total of 9 injections. Thereafter the rabbits were trial-bled from the 
margixial ear vein at three-day intervalŝ  and the serum agglutinin 
titer determined. The titer reached its peak on the 26th day after the 
last injection and then it started to decrease. On the 28th day the 
rabbits were given another subcutaneous dose of 2,0 ml of unbroken 
washed cell suspension containing 9 z 10̂  cells per ml. The 
agglutinin titer was again followed. Fifteen days after the booster 
dose, when the agglutinin titer was high, the rabbits were bled to 
death from the heart. The serum was obtained and stored in the frozen 
state (-20° C). 
Agglutinin titrations Serial two-fold dilutions of the antiserum 
were made in 1*100 normal rabbit serum in saline. Saline and 1(100 
normal rabbit serum in saline were used as controls. To 0,5 ml of the 
respective dilutions, 0,5 ml of a suspension of tumor cells (washed 
four times) in saline containing it x 10̂  cells per ml was added. The 
tubes were thoroughly shaken and allowed to stand at room temperature 
for 2 hours and then overnight in the refrigerator. The results were 
then recorded as -, ff-f, & ffj-f depending on the degree of 
clumping of the tumor cells noticed after shaking the tubes gently. 
In reading this agglutination every tube was compared with the normal 
rabbit serum and the saline controls. 
Technic of absorption of the rabbit antiserum; 
A. Specific absorption with washed tumor cells; Tumor cells 
obtained from 5.0 ml of ascites fluid were washed h times with saline 
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and then sedimented» These sedimented cells were then added to 12,0 ml 
of rabbit antiserum (titer 1g2560), mixed thoroughly and allowed to 
stand in the refrigerator. Twenty-four hours later, the antiserum was 
separated by centrifuging at 12,000 rpm for 15 min. Fresh tumor cells 
obtained from 5*0 ml of ascites fluid were washed it times with saline, 
sedimented, and then added to this antiserum. This was repeated and 
the agglutinin titer determined after each absorption» At the end of 
the 7th absorption, only slight and doubtful agglutination was observed 
in 1*2 and l;lt dilutions. This antiserum was then filtered through a 
No. 12 Handler bacterial filter and stored in the frozen state (-20° C). 
B, Non-specific absorption with normal mouse liver and spleens 
Liver and spleen obtained from 3 normal CFW female mice (about 5-'week 
old) were washed twice with saline and then cut into small pieces. 
These pieces were washed once with saline and then sedimented from 
saline suspension by centrifuging at 5̂ 000 rpm for 15 min. These 
sedimented pieces were then added to 12.0 ml of rabbit antiserum 
(titer 1:1,280) and mixed thoroughly. This suspension was allowed to 
stand in the refrigerator. After 2h hours, the antiserum was separated 
by centrifuging at 5,000 rpm for 20 min and fresh liver and spleen 
pieces (washed with saline) obtained from 3 female CFW mice were added 
to it. This suspension was allowed to stand in the refrigerator for 2k 
hours and at the end of this period the antiserum was separated. The 
absorption was repeated 7 times. At the end of the 7th absorption, the 
agglutinin titer was found to be 1&512. The dilutions showing maximum 
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agglutination were found to be l*l60 and 1:320. This absorbed 
antiserum was filtered through a No. 12 Handler bacterial filter and 
stored in the frozen state (-20° C), 
CHAPTER IV 
EXPERIMENTAL RESULTS 
I. Preliminary studies? 
Experiment 1. Minimum number of tumor cells necessary to produce 
ascites in female GFW mice. Two dilutions of ascites fluid were made 
in saline, one containing 1,000 and the other 20,000 cells per ml. 
These suspensions were injected into mice in varied doses as showi in 
Table I. Mice in group I were injected with 0,2 ml of the cell 
suspension containing 1,000 cells per ml, or 200 tumor cells per mouse. 
All other groups were injected with varied amounts of the suspension 
containing 20,000 cells per ml. It is evident from the results in 
Table I that the time required by the tumor to manifest itself in the 
form of recognizable ascites varied inversely with the number of tumor 
cells in the transplant. With a dose of 200 cells ascites was notice­
able on the 28th day in only 3 of 10 mice injected. With a transplant 
of 16,000 tumor cells, however, ascites was noticed in a few mice by 
the 6th day after the challenge, and 10 of 10 mice developed ascites 
by the l̂ th day. 
Experiment 2. Comparative susceptibility of female mice of the 
GFW and CFl strains, Tumor fluid obtained separately from CM and CFl 
mice was used for challenging the tro breeds of mice. Cell suspensions 
with varied cell concentrations were injected into groups of 5 mice 
as shown in Table II. The incidence of ascites was recorded on the 
l̂ th and 28th day after the challenge. From the results in Table II, 
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TABLE I 
MINIMUM NUMBER OF TUMOR CELLS AND ASCITES 
No. of Positives* on (days) 
Group calls 6th 8th 10th iSth 20th 28th 31st 
I 200 3/10 7/10 
II 1000 — M wm - U/5 
III 2000 " ' # •w — 9/10 10/10 10/10 
IV liOOO mm 10/10 10/10 10/10 10/10 
V 8000 mm — 3/10 9/10 PAo 9/10 9/10 
VI 16000 1/10 3/10 Vio 10/10 10/10 10/10 10/10 
* Mice that showed growth of timor in the form of obvious ascites are, 
hereafter, mentioned as "Positives," 
TABLE II 
COMPARATIVE SUSCEPTIBILITY OF CFl AND CFI MICE 
Challenge CFI CFW 
(No. of ce Us No. of positives on 28th 
Group in thousands) day 
I 1 5/5 k/5 
II 2 5/2 k/5 
III k 5/5 5/5 
]T 8 5/5 5/5 
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there appears to be no marked difference in the susceptibility of the 
two strains of mice. However̂  in general, the CFl mice appeared to be 
slightly more susceptible than the GFW strain. 
Experiment 3« Growth curve of the Bhrlich ascites tumor and 
differential blood count on the tumorous mice. Seventy female Hamilton 
mice, each about 5- to 7-week old, were injected with 0.2 ml of the 
ascites fluid obtained from female Hamilton mice in which the tumor was 
10 days old. Groups of 5 mice were bled from the infra-orbital sinus 
on the desired day and smears made. These smears were stained with 
Wright's stain and differential white-blood-cell counts performed. 
After the fourth day of challenge when the ascites became manifest, 5 
mice were randomly selected daily, tapped for ascitic fluid, then bled 
and discarded. Daily cell counts were performed on the tumor fluid 
thus obtained. The averages of the cell counts of fluids obtained 
from 5 different mice at the various time intervals investigated were 
plotted (Fig, 1). Differential white-blood-cell counts were performed 
on each of five smears and the results were averaged and plotted 
(Fig. 2). 
It is evident from Fig. 1 that the tumor cell count of the ascitic 
fluid per unit volume was highest from ̂  to 7 days after the tumor 
transplantation. At this time the cell count was found to be around 
15-20 X 10̂  cells per ml. Thereafter, the cell count per volume 
decreased progressively until about the liith day when it was as low as 
7 X lo7 cells per ml. The ascites, however, progressed and the 
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FIGURE 1. 
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FIGURS 2 
DIFFERENTIAL W.B.C. COUNT ON BLOOD SMEARS OP TUMOROUS MICE 
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abdoiJien became more and more distended, till about the 18th to 20th day 
when the animals died. 
The differential blood count (Fig. 2) showed a progressive rise in 
the neutrophils and a progressive decrease in lymphocytes. Eosinophils 
showed no noticeable change. The large monocytes increased gradually, 
reaching the highest percentage (20%) on the 11th or 12th day. 
II, Active specific immunization: 
Experiment Lowest concentration of formalin required to kill 
the tumor cells. A tumor cell suspension with a cell count of 5 x 10 
cells per ml was mixed with 2,0% formalin in saline, and saline in 
different proportions to obtain the desired concentration, as shown in 
Table III. Then the mixture was allowed to stand at room temperature 
for 1 hour. After this period, it was kept in the refrigerator for l6 
hours. At the end of l6 hours, it was injected into female Hamilton 
mice in doses of 0.2 ml per mouse. An untreated cell suspension with 
the same cell count was used as control. The number of mice that 
developed ascites was recorded on the l5th day after the injection. 
The results in Table III show that a concentration of formalin between 
0.25 and 0.125% was required to kill the tumor cells, From these 
results it was decided to use 0,2% formalin solution to prepare vaccines. 
Experiment 5» Immunization of mice with formalin-killed cells. 
Formalin-treated cells were prepared as described in the section on 
materials and methods, and injected intraperitoneally in female CFW 
mice in 0.2 ml doses. Three inmunizing injections were given at four-
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TABLE III 
EFFECT OF FORMALIN ON THE TUMOR CELLS 
Formalin Call sus- Final Positives 
2% pension Saline concentration total mice 
2.0 ml 2,0 ml - 1% O/k 
1.0 ml 2.0 ml 1.0 ml 0,5% O/h 
1.0 ml 2.0 ml ^.0 ml 0.2$$ 0/1+ 
0.5 ml 1.0 ml 6.5 ml 0.125$ 2/k 
Controls cells on]y h/h 
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day intervals. Then the mice were divided into 3 groups. Group I was 
challenged 6 days after the last injection, group II, 10 days, and 
group III, lii days after the last vaccination. The challenging dose 
consisted of 5,000 tumor cells. Observations as recorded on the 20th 
day after challenge are shown in Table IV, The results show that the 
induced immunity increased with time after the last vaccination. It 
was most marked on the lî th day after the last vaccination, when only 
19.8% of the mice developed the tumor as compared to 72,5 and ii2,5̂  
on the 6th and 10th day, respectively. 
Sjçeriment 6» Lowest concentration of phenol required to kill the 
tumor cells, A tumor cell suspension with cell count of 5 x 10̂  per ml 
was prepared and mixed with varying amounts of 1% phenol in saline, and 
plain saline in order to obtain the desired concentration of phenol 
according to the protocol in Table V, The suspension was kept at room 
tenperature for one hour and in the refrigerator for 16 hours. At the 
end of this period, the cells were separated from the phenol solution 
by centrifugation at 2,000 rpm for 5 min and then washed once with 
saline to remove the excess phenol. The sedimented cells were resus­
pended in saline, TWo-tenths ml of this suspension was injected 
intraperitoneally into each mouse. Washed tumor cells not treated with 
phenol were used as controls. The results indicated that the lowest 
concentration of phenol that was required to kill the tumor cells under 
the specified conditions was between 0,5 apd 0,8%, Therefore, 0,8% 
phenol was employed to prepare the vaccines. 
Experiment 7. Immunization of mice with phenol-killed tumor cells. 
Pour intraperitoneal injections of phenol-killed vaccine were given at 
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TABLE IV 
IMMimiZAIION WITH FOBMALDJ-KILLBD CELLS 
Group 
No. of 
vaccn. 
Time of challenge 
after last vaccn. 
Positives 
total mice % Positives 
I 3 6 days 29/kO 72.5^ 
la control M 6 days 5/5 100,0* 
II 3 10 days 17/Lo 12.52 
Ila control mm 10 days V5 80.0% 
III 3 lU days 6/30 19.8% 
Ilia control 14 days 30/30 100.0% 
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mBLE V 
EFFECT OF PHENOL ON TUMOR CELLS 
Phenol Cell Pinal Positives 
Gfcroup 1% suspension Saline concn. total mice 
I 5.0 ml cells frcm 1.0% 0/5 
1.0 ml 
II U»0 ml .1.0 ml — 0.8* q/5 
III 2.0 ml 2,0 ml — 0.# 
I? 1.0 ml 2,0 ml 1,0 ml 0.22% 5/5 
V 1.0 ml 2,0 ml S,0 ml 0.125$ vs 
VI mm cells only —* — 
control 
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b-day intervals. Fourteen days after the last vaccination, the mice 
were challenged with 5jOOO tumor cells. The results on the 20th day 
after the challenge are given in Table VI. The protection resulting 
from the administration of phenol-killed vaccine was weak. 
Experiment 8. Lowest concentration of merthiolate required t_o 
kill the tumor cells. Tumor cell suspension with 5 x 10̂  cells per ml 
was prepared and mixed with 1:1000 merthiolate solution and saline in 
varying proportions as shown in Table VII in order to obtain the 
desired concentration of merthiolate. This suspension was kept at 
room tençierature for one hour and then in the refrigerator for 16 
hours. It was then injected intraperitoneally in mice in doses of 
0.2 ml per mouse. Washed untreated cells were used as controls. The 
results in Table VII show that a merthiolate concentration of IsSOOO 
was the lowest concentration that would kill the tumor cells under the 
specified conditions. This concentration was employed for killing 
tumor cells in the preparation of vaccines. 
Experiment 9. Immunization of mice with merthiolate-killed tumor 
cells. Three intraperitoneal injections of 0.2 ml of the merthiolate-
killed cells were given at U day intervals. Fourteen days after the 
last immunizing injection, the mice were challenged with 5#000 tumor 
cells. The results recorded on the 20th day after the challenge are 
shown in Table VIII. Only 11 of the 30 immunized mice developed .the 
tumor after c&allenge while 30 of 30 control mice developed the tumor 
after a similar challenge. 
Experiment 10. Minimum dose of ultraviolet light required to kill 
the ascites tumor cells. Ten ml aliquots of a 1:100 dilution of the 
TABLE VI 
BfflRMIZATION WITH PHSMOL-KILLED TUMOR CELLS 
No. of Positives 
Group vaccn. total mice % Positives 
I It 29A0 72.5$ 
II - 39A0 97.5^ 
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TABLS VII 
EFFECT OF MBBTHIOLATB ON TUMOR CELLS 
Merthiolate Cell Final Positives 
Group lilOOO suspension Saline concn. total mice 
I 2,0 ml .2.0 ml - 1:2000 0/5 
II 1.0 ml 2.0 ml 2.0 ml ItSOOO 0/5 
III 1.0 ml .2.0 ml 7.0 ml 1:10000 1/5 
17 0.5 ml 1.0 ml 6.0 ml 1:15000 5/5 
V - cells only - - 5/5 
control 
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TABLE VIII 
IMMUNIZATION WITH MERTHIOLATB-KILLBD TIMOR CELLS 
 ̂ No. of Positives"  ̂
Group va con» total mice % Positives 
I 3 11/30 36.3% 
II - 30/3a 100.0$ 
controls 
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ascitic fluid were exposed in Petri dishes to ultraviolet light for 
different lengths of time as shown in Table IX, Two-tenths ml of this 
ultraviolet-treated fluid was injected intraperitoneally into mice 
within 30 min after irradiation. Unirradiated fluid containing the 
same concentration of cells was used as a control. An exposure of 10 
min or more was required to kill the tumor cells. Ten and fifteen min 
exposures were ençloyed for the preparation of vaccines. 
Experiment 11, Immunization of mice with ultraviolet light-killed 
tumor cells. Four intraperitoneal injections of 0,2 ml of vaccines 
irradiated for 10 and 1$ min were given at i|.-day intervals. Two weeks 
after the last vaccination the mice were challenged with 5,000 tumor 
cells. The results obtained on the 20th day after the challenge are 
given in Table X, Only 5 of 30 mice vaccinated with tumor cells 
irradiated for 10 min and only ij. of 30 mice vaccinated with the vaccine 
irradiated for 15 min developed the tumor after challenge. All the 30 
unvaccinated controls developed ascites. 
Ill, Non-specific immunization; 
Experiment 12, Non-specific immunity induced by incomplete 
Freund's adjuvant mixture. Forty GFW female mice were injected intra­
peritoneally with 0»2 ml of inconçtlete Freund's adjuvant mixture. 
Another control group consisting of I4.O mice received sterile saline 
instead of the adjuvant mixture, One week later both groups were 
challenged with 5,000 tumor cells. Observations were recorded on the 
20th and 28th days after the challenge. The results shown in Table XI 
indicate that Freund's adjuvant has a marked capacity to increase the 
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TABLE IX 
EFFECT OF ULTRAVIOLET LIGHT OM TUMOR CELLS 
Time of irradn. Positives 
Group in min total mice 
I 8 2/^ 
II 10 0/5 
III 15 0/5 
IV 20 0/5 
7 25 0/5 
VI - 5/5 
control 
-&0— 
TABLE X 
IMMUNIZATION OF MICE WITH ULTRAVIOLET LIGHT IRRADIATED CELLS 
Time of Positives 
Group irradn, total mice % Positives 
I 10 min 5/30 l6,5% 
11 I5 min h/30 13.2% 
III - 30/30 100.0% 
controls 
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mELE 21 
EFFECT OF INCOMPLETE FREUND'S ADJUVANT 
. Positives/total lio» of mice on 
— 28th day 
I . 3/10 ^/ItO 
(F. Adjuvant) 
II 3k/kO 39/hO 
(Saline) 
» Each group consisted of i|.0 female CFlff mice. 
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resistance of the mice toward an intraperitoneal challenge of the tumor. 
Experiment 13. Duration of non-specific resistance induced by 
incomplete Freund's adjuvant mixture. Mice treated with 0.2 ml incom­
plete Freund's adjuvant mixture were challenged with 5̂ 000 tumor cells 
at different intervals as indicated in Table XII., Mice treated with 
saline instead of Freund's adjuvant served as controls. The results 
given in Table XII and Fig. 3 show that the protective effect of Freund's 
adjuvant is not manifested until 5 to 8 days after its administration. 
-On the 10th and l5th day the mice were highly resistant to the tumor. 
These mice were actually immune to the challenge of 5̂ 000 tumor cells 
since they were still tumor-free 45 days after the challenge. 
Experiment 14. Non-specific iianunity -Induced by zymosan. Five-
hundredths gm (0,05 gm) of zymosan was suspended in 10.0 ml saline and 
to 8.0 ml of this suepnsion was added 2.0 ml of saline. This suspension 
now contained 400 pgm of zymosan in 0.1 ml. Two-tenths ml of this 
suspension was injected intraperitoneally into each mouse. The controls 
received 0.2 ml of sterile saline. The mice were then challenged with 
5,000 tumor cells at different intervals of time as shown in Table XIII. 
The results (Table XIII and Fig, 4) indicate that the non-specific 
inmiunizing effect of zymosan was highest when it was given simultane­
ously with the tumor. This effect decreased gradually until the seventh 
day when little or no effect was demonstrable. 
Experiment 15. Non-specific immunity induced by killed Bordetella 
pertussis cells. Two billion B. pertussis cells suspended in 0.2 ml of 
saline were injected intraperitoneally into female CFW mice. The control 
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TABLE XII 
DUBATION OF EFFECT, OF INCOMPLETS FBEUMD'S ADJUVANT 
No. of Treated with Time of No. of positives on 
Qroup mice Adj. Saline challenge 20th day 28th day 
I 10 f -2ii hrs 6/10 7/10 
II 5 4" ~2k hrs 5/5 
III 10 + •w- 0 hrs 6/10 7/10 
IV 5 «s» + 0 hrs 5/̂  5/5 
V 10 + 2b his 6/10 6/10 
VI 5 — + 2I4. hrs S/̂  5/5 
VII 10 + am 5 days 6/10 6/10 
VIII 5 + 5 days 5/5 
IX 10 10 days 0/10 0/10 
X 5 — 10 days 5/5 5/5 
XI 10 + 15 days 1/10 1/10 
XII 5 - 15 days 5/5 5/5 
* These mice were again observed on the U5th day after challenge. In 
group H, one mouse had developed ascites while th$ other 9 did not* 
In group XIj all the nine mice remained healthy at this time. 
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FIGURE 3. 
NON-SPECIFIC IMMUNIZING EFFECT OF INCOMPLETE FREUND*S ADJUVANT 
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TABLE XIII 
NON-SPECIFIC IMMUNITY INDUCED BY ZYMOSAN 
No. of Treatment Time of No. of positives on 
Group mice zymosan saline challenge 20th day 28th day 
I 10 "f 0 hr s o/io 2/10 
II 10 — + 0 hrs 10/10 loAo 
III 10 + M* 2k hrs lAo /̂lo 
IV 10 - + 2ii hrs lOAO 10/10 
V 10 + — 3 days 2/10 2/10 
VI 10 i 3 days 9A0 10/10 
VII 10 + 7 days 8/10 8Ao 
VIII 10 - 4 7 days 10/10 10/10 
FIGURE 4 
NON-GPEGIFIC IMMUNIZING SFFECT OF ZYMOSAN 
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mice received 0,2 ml of saline instead of the B. pertussis cells. 
Subsequently, these mice were challenged with 5,000 tumor cells at 
different intervals of time as shown in Table XIV* B. pertussis cells, 
when injected simultaneously with or after the tumor had very little 
effect in enhancing the defense of the mice towards the tumor challenge 
(Table XIV and Fig. 5). However, there was a progressive increase in 
immunity until the 5th day after B. pertussis treatment when 8 of 10 
mice did not develop ascites on the 20th day after challenge and 6 of 
10 mice did not show any evidence of tumor growth on the 28th day after 
the challenge. This protective effect of B, pertussis decreased after 
5 days, and little protection was observed 18 days after B, pertussis 
treatment. 
Experiment 16» Non-specific immunity induced by Escherichia coli 
lipopolysac char ide » Two and five-tenths mg of the endotoxin were dis­
solved in 25.0 ml of saline. This solution contained 100 |agm of 
endotoxin per ml. Two-tenths ml of this solution containing 20 )igm of the 
endotoxin was injected intraperitoneally into each mouse. The controls 
were injected with 0.2 ml sterile saline. These mice were challenged 
with 5,000 tumor cells at different intervals of time as shown in 
Table XV, As is evident from the results in Table XV and Fig. 6, there 
was an increased resistance to tumor transplants when the lipopolysac-
charide was given simultaneously with, or 2k hours after the challenge. 
This protective effect was still noticeable 21̂  hours after the adminis­
tration of the endotoxin, but decreased progressively thereafter, until 
the 10th day when little or no protection could be demonstrated. 
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TABLE XIV 
N0N-3PSGIFIC IMMUNITY INDUCED BY B. PEETHSSIS CELLS 
Treatment Time of No. of positives on 
Group* B» pertussis Saline challenge 20th day 28th day 
I + -2U hrs 7/10 9/10 
II + -2k hrs 10/10 10/10 
III + 0 hrs 5Ao 7/10 
17 + 0 hrs 10/10 10/10 
V + mm 5 days 2/10 4/10 
VI 4 5 days 10/10 10/10 
VII + 8 days 6Ao 6/10 
VIII «M + 8 days 10/10 10/10 
IX 12 days 3/10 S/10 
X f- 12 days 10/10 10/10 
XI + 18 days 6/10 6/10 
XII + 18 days 10/10 10/10 
* Each group consisted of 10 female CF¥ mice 
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FIQURE 5. 
NON-SPECIFIC IMMUNIZING EFFECT OF B. pertussis CELLS 
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TÂ  27 
NON-SPECIFIC IMMUNITY INDUCED BY 3. COLI ENDOTOXIN 
Treatment Time of No., of positives on 
Group* endotoxin saline challenge 20tn day 28th day 
I 4- -Zk hrs Vio 6/10 
II — + -2Ù hrs 5/5 
III + 0 hrs 6/10 8/10 
IV a* + 0 hrs vs 5/5 
V 4 2k hrs 6/10 10/10 
VI aw + 2li hrs 5/5 5/5 
VII f •M. 5 days 7/10 9/10 
VIII ». 5 days 5/5 5/5 
IX + -Î* 10 days 8Ao 9/10 
X — •h 10 days 5/5 5/5 
* The controls (groups IÎ  IV̂  ¥1, VIII and X) consisted of 5 mice in 
each groupJ whereas the other groups consisted of 10 mice. 
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FIGDEE 6 
NON-SPECIFIC IMMUNIZING EFFECT OF E. coli ENDOTOXIN 
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IV. Effect of rabbit antiserums 
Experiment 17. ̂  vitro neutralization of the tumor by rabbit 
antiserum, A 1;80 dilution of rabbit antiserum (agglutinin titer 
1/2560) which produced strong agglutination was used. Washed and 
sedimented tumor cells were resuspended in this dilution to obtain a 
final concentration of 20,000 cells par ml. As a control a similar cell 
suspension was prepared in normal rabbit serum obtained from the same 
rabbit before immunizing injections were given. A second control con­
sisted of a saline suspension containing 20,000 tumor cells per ml. 
These 3 suspensions were incubated in a water bath at 37° C for 1 hour. 
Half an hour later the tubes were shaken and 0.2 ml of the corresponding 
suspension injected into each of 10 mice. The results were recorded on 
the 20th and 28th days after challenge (Table XVI)» These results show 
that the tumor cells are almost completely neutralized after incubation 
with the antiserum, while not affected by normal rabbit serum or saline. 
Experiment 18. Passive immunization with rabbit antiserum. Sixty 
female CFHf mice were divided into 6 groups of 10 mice each. They were 
all challenged with U,000 tumor cells, and subsequently given 1 to 5 
intraperitoneal injections of 0.1 ml of the undiluted antiserum (titer 
1/2560) at different intervals as shown in Table XVII. The results, 
recorded on 20th and 28th day after the challenge, indicate that treat­
ment with antiserum 2k hours before the challenge had only slight pro­
tective effect, but two or more injections given on 0 and 1 day after 
the challenge, completely protected mice against the tumor transplant. 
Normal rabbit serum and saline failed to produce this effect. 
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TABLS XVI 
IN VITRO NEUTRALIZATION WITH ANTISERUM 
Group 
Cells 
treated with 
Positives 
total mice 
20th day 
Positives 
total mice 
28th day 
I antiserum lAo 1/10 
II N.R.3. loAo 10/10 
III saline 10/10 10/10 
* Each group contained 10 female GFE mice. 
TABLE XVII 
PASSIVE IMMTOI2ATIQN IRITH ANTISBfflJM 
Time of injecting the reagent 
Group -2k hrs 0 hr 1 day 2 4 days 
No. of positives on 
Antiserum ; 
I + — «=»' ». "=• 1 
II + - W- - — 
III f + M» CM. 
IV - + + t - M 
V - + + M. — 
VI — + + f + f — 
Normal Eabbit Serum; 
I + mm M — — 5 
II f — - mm 5 
III -» + t- ** — 5 
IV + + + - 5 
V « + + + f — 5 
VI — + + + f h 
Saline s 
I + — «• — «** 5 
II «=> + —• — — 5 
III + + - «0 5 
IV on + +• + •M 5 
7 + + + + 5 
VI — f + f f + 5 
S/io 
0/10 
2/10 
0/10 
1/10 
0/10 
s/̂  
S/5 
VS 
VS 
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Experiment 19. Neutralization of the tumor with antiserum absorbed 
with washed tumor cells. Babbit antiserum absorbed with tumor cells 
(as described in the section on Materials and Methods) was used, A 
1;80 dilution of this absorbed antiserum was prepared and in it were 
suspended washed tumor cells to make a final cell concentration of 
20,000 cells per ml. Similar suspensions were prepared in Is80 dilu­
tions of agglutinating and normal rabbit serum, to be used as controls. 
These cell suspensions were incubated at 37° C in a water bath for 1 
hour and 15 min later were injected intraperitoneally into mice (0.2 ml 
per mouse). The results obtained on the 20th, 28th and Uoth day after 
challenge are shown in Table XVIII, These results show that antiserum 
absorbed with tumor cells failed to neutralize the oncogenic property 
of the tumor cells. 
Experiment 20. Passive immunization with heated and specifically 
absorbed antiserum. Groups of 10 mice were challenged with 5,000 tumor 
cells and subsequently given 3 intraperitoneal injections of 0,1 ml of 
the respective antisera at 0, 2k and 72 hours after the tumor trans­
plantation. Agglutinating antiserum heated in a water bath at 56° C 
for 1 hour was used as heated antiserum. The results shown in Table XIX 
indicate that no passive immunization was possible with the absorbed 
antiserum. Heated antiserum, however, retained its immunizing property. 
Experiment 21. In vitro neturalization with non-specifically 
absorbed antiserum. Rabbit antiserum absorbed with normal mouse liver 
and spleen (as described in the section on Materials and Methods) was 
used for this experiment as well as experiment No. 22. Normal rabbit 
—56-
TABL2 ZVIII 
EFFECT OF SPECIFICALLY AB03RBED ANTISERUM 
C e l l s P o s i t i v e s / t o t a l  n o .  o f  m i c e  o n  
Group treated with 20th day 28th day IjOth day 
I Antiserum O/lO O/lO O/lO 
II Absorbed 
antiserum 8/10 9/10 9/10 
III N.R.S. 10/10 10/10 10/10 
-^7-
TABLE XIX 
EFFECT OF HS&TSD AND ABSOBBED ANTISSEQU 
Cells Positives/total no. of mice on 
Group treated Tsrith 20th day 28th day Loth day 
I Antiserum 0/10 0/10 0/10 
II Heated 
antiserum 0/10 0/10 1/10 
III Absorbed 
antiserum 9/10 10/10 discarded 
IV N.R.S. 10/10 
10/10 
10/10 discarded 
7 Saline 10/10 discarded 
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serum and specifically absorbed antiserum were used as controls. The 
dilutions used were IjlO and 1:120. The results shown in Table XX 
indicate that non-specific absorption of the antiserum lowered its 
ability to neutralize the tumor cells, but did not render it conpletely 
inactive. 
Experiment 22. Passive immunization with non-specifically absorbed 
antiserum» The antiserum used was the same as for experiment 21, above. 
Groups of 10 mice were challenged with 5̂ 000 tumor cells and subsequnently 
treated with the respective serum. Three injections of 0.1 ml of the 
serum were given 0, 2k and 72 hours after the tumor transplant. 
Controls were treated with unabsorbed, specifically absorbed and normal 
rabbit serum. The results shown in Table XXI indicate that non­
specific absorption did not affect the protective power of the antiserum 
when compared to that of the unabsorbed antiserum. 
-B9~ 
TABLE XX 
IN VITRO EFFECT OF NON-SPECIFIC ABSORPTION 
Positives/total no. of mice on 
20th day 28th day l̂ Oth day Group 
Cells 
treated with 
I lîlÔ  
(Antiserum 0/5 0/5 
II 1:120) 0/5 0/5 
III lllOx 
, (Sp. absorbed 5/5 5/5 
(antiserum 
IV ltl20) 5/5 5/5 
V IÎION 
/Non-nsp, abs. 1/5 3/5 
(antiserum 
VI ltl20) V5 V5 
VII lilO'N 
\N.R.S. 5/5 5/5 
VIII 1*120) 5/5 5/5 
% 
discarded 
on 28th day 
3/5 
V5 
discarded 
on 28th day 
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TABLE m 
IN VIVO EFFECT OF NON-SPECIFIC ABSORPTION 
C e l l s P o s i t i v e s / t o t a l  n o ,  o f  m i c e  o n  
Group treated with 20th day 28th day LOth day 
I Antiserum O/lO l/lO 5/10 
II Sp. absorb. 7/10 10/10 
antiserum discarded 
III Noa-sp. abs. O/lO 2/10 
antiserum 
IV N.R.S. 5/10 10/10 
discarded 
CHAPTER V 
DISCUSSION 
The experimental results seem to indicate that tumor cells treated 
with ultraviolet light, formalin and merthiolate (thimerosal) can induce 
immunity against a subsequent challenge of about 5,000 tumor cells. 
Ultraviolet light gave the best results (about 80% protection). In 
demonstrating this immunity one has to bear two facts in mind; 
1) actively immunized mice may tolerate only snail challenge doses 
since the induced immunity may not be sufficiently strong to protect 
the animals against heavier challenges, and 2) the time after immuni­
zation, at which the challenge transplant is given is inportant because 
the induction of immunity is a gradual process, which reaches its 
maximum level at different times depending on the type of antigen, the 
amount given, the route of administration and perhaps other factors. 
The time factor is illustrated by the results obtained with formalinized 
vaccines. A challenge given 6 days after the last vaccination was 
tolerated by 27.2% mice, whereas that given on the llith day was toler­
ated by 80%, 
In order to explain the possible mechanism of action of agents 
which render the tumor cells capable of inducing active immunity, one 
should consider the homograft reaction. Apparently, the tumor grows 
and kills the host because it fails to evoke the antibody response 
necessary for its rejection. This may be due to the fact that the gen­
etic make-up of the tumor cells is such as to make them an isologous 
transplant rather than a heterologous or homologous transplant. 
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According to the genetic concept of the transplantation reaction intro­
duced by Gorer (itS), any agent that is able to alter the genetic make­
up of the tumor cells in such a way that it becomes non-allelomorphic 
to the normal mouse tissue, will render the tumor cells antigenic to 
the mouse. The previous experiments with x-rays (62) and nitrogen-
mustard (63), and our observations with ultraviolet light and formalin, 
seem to indicate that all these agents that have been employed success­
fully for immunization experiments, belong to the same group of agents 
called "mutagenics" (90). If mutations were responsible for this 
change in antigenicity, one would expect the tumor cells to multiply 
after they have been treated with the agent. This might be true at 
least in case of the x-irradiated tumor cells (89). 
Another possible mechanism by which immunity could be induced 
would involve the presence of an active antigen in the tumor cells to 
which the host may develop antibodies. In normal mice these antibodies 
will not develop rapidly enough to protect the animal against the 
rapidly multiplying tumor cells. However, according to this hypothesis, 
any agent that is able to destroy the carcinogenic property of the 
tumor cells without affecting the "specific protective antigen," could 
convert the tumor cells into a vaccine capable of protecting the 
animal against subsequent transplants. That this hypothesis may indeed 
be true is indicated by the reports demonstrating specific antibodies 
in animals with actively growing tumor cells (52, 53), and in rabbits 
immunized with specific antigens obtained from neoplasms (5L, 55). 
Specific neutralizing antibodies have also been demonstrated in chickens 
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3 to 5 weeks after the regression of Rous sarcoma (5l). The main 
difficulty here appears to be the fact that in the presence of actively 
growing tumor cells it is difficult to demonstrate specific antibodies, 
although they have been demonstrated against Shope Papilloma and Brown-
Pearce Carcinoma in rabbits (52, 53)* 
Still another possible way in which these vaccines could stimulate 
immunity is through a non-specific host-defense mechanism. Earlier 
work by Pellimer, Landy and Shear (69), has shown that tissue-poly sa c-
charides derived from normal and malignant (Sarcoma 37 and Carcinoma 
21:1-6) mouse tissue, have the property of increasing the host resistance 
to bacterial infections by altering the serum properdin levels. 
Repeated injections of killed tumor cells may cause this effect. The 
fact that non-specific immunity would ordinarily not be expected to 
offer complete protection in as great a percentage of mice as specific 
immunity would, bears but little significance in view of the non­
specific immunity that has been induced through treatment with incomplete 
Freund's adjuvant mixture in our experiments. 
The fact that phenol-killed and merthiolate-killed tumor cells 
produced only weak immunity, can probably be explained by assuming that 
these agents destroyed or altered the antigenicity of the tumor cells, 
so that they were not capable of evoking a stror̂  antibody response. 
Results with agglutinating antiserum prepared in rabbits indicated 
that this antiserum was capable of neutralizing to vitro the carcino­
genic property of the tumor cells. This agrees with the results of 
Flax (80), This antiserum also protected mice against a challenge of 
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5,000 tumor cells if 3 or more intraperitoneal injections of 0,1 ml of 
the antiserum were given» This protective property of the antiserum was 
lost after repeated absorption with tumor cells, strongly suggesting the 
presence of specific antibodies to the tumor. Specifically absorbed 
antiserum also lost its agglutinating capacity, while antiserum absorbed 
with normal mouse tissues still retained the agglutinins as well as its 
protective properties against the tumor. Earlier results of Flax (80) 
and Horn (81) indicated that treatment of mice with antiserum only 
prolonged their survival period. The challenge used by these workers 
was large (0,1 ml of the tumor fluid or about 1 x 10̂  tumor cells per 
mouse). In our ê çieriments complete protection was obtained with a 
challenge dose of 5,000 tumor cells. Contrary to the findings of Flax 
(80), guinea pig complement was not found necessary to show ̂  vitro 
neutralization of tumor cells. In the present work it has been clearly 
shown that normal rabbit serum does not have the capacity to neutralize 
the tumor cells either to vitro or to vivo. 
The antiserum prepared against washed tumor cells will certainly 
be expected to contain antibodies against normal mouse tissue, since 
the mice used were not genetically homogeneous. The role that these 
antibodies might have played in the present work was ruled out by 
absorbing the antiserum with normal mouse tissue and showing that its 
protective property was not removed to this way. The results obtained 
by Horn (81) indicated that antisera prepared against normal mouse 
liver and spleen tissue had no neutralizing effect on the Shrlich 
ascites tumor cells. This in conjunction with our observation that 
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absorption of the antiserum with tumor cells removed the agglutinating 
as well as neutralizing power of the antiserum, favors the postulation 
that specific antibodies may be responsible for the protective activity 
of the immune serum. 
From the results presented in this thesis, it is also evident that 
in addition to specific immunization, non-specific agents also are 
capable of producing immunity to Ehrlich ascites tumor. Bacterial 
endotoxins and lipopolysaccharides from plant and animal sources have 
been known to alter the resistance of the host towards infections if 
given in very small doses (70, 71, 72, 73). In our experiments, 
zymosan, E. coli endotoxin, B. pertussis cells and incomplete Freund's 
adjuvant appeared to increase the resistance of mice towards subsequent 
tumor transplants. Not only the survival time was prolonged, but in 
the case of Freund's adjuvant, the mice appeared to tolerate coupletely 
a challenge of 5,000 tumor cells. The mechanism involved here is not 
yet known. Various host defense mechanisms have been incriminated. 
The increase in lysozyme, properdin and phagocytic acitivity of cells 
have been chiefly considered. As shown by Hook and his co-workers (87), 
the serum lysozyme and properdin levels showed an initial drop followed 
by a marked rise after an intraperitoneal injection of 1,0 mg of 
zymosan in mice. Serum lysozyme did not rise above normal levels until 
about the 3rd day after the administration of polysaccharide. The 
properdin level took still longer to show a rise above normal. Ten 
days after the administration of zymosan, the properdin level was about 
l60% of normal values, and remained high for about 32 days. The serum 
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lyaozyma level dropped after about 16 days. Earlier work of Pellimer, 
Landy and Shear (6̂ ), had shown that the injection of tissue polysac­
charides derived from animal tissues led to a rise in properdin level 
noticeable 12 to 2k hours after administration of the polysaccharide. 
The results obtained with zymosan and E, coli endotoxin could possibly 
be explained on this early rise of properdin level. In the case of 
Freund's adjuvant and B, pertussis, this explanation does not seem to 
apply. However, according to Hook et al. (87), properdin and lysozyma 
level and the leukocyte count showed marked rise only about 7 days 
after zymosan injection, and the properdin level remained high for 32 
days. If this is the case when Freund's adjuvant is injected, the 
properdin system might well explain the protective activity of this 
agent. The protective effect of B. pertussis may be different. 
Properdin level might not be the only factor involved, however, since 
Hook et al. (87) have shown that after the administration of zymosan, 
the properdin level reached its peak 10 days after injection of the 
substance and it remained high for about 30 days. The protection 
against Zhrlich ascites tumor obtained in the present work did not 
follow this pattern except in the case of Freund's adjuvant. 
It is interesting to note that the protection produced by the 
agents-tested, did not manifest itself at the same time. With zymosan, 
for example, the protective effect was demonstrated within 2h hours, and 
disappeared after 6 days. With B, pertussis cells, the maximum protec­
tion was noticed on or about the 6th day, while with Freund's adjuvant 
the protection was marked only 7 days after and persisted for at least 
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15 days. These facts seem to suggest that more than one non-specific 
mechanism may be involved for these agents. A study of serum properdin 
level, lysozyme level and the phagocytic index following the adminis-
tration of these agents is suggested. This may give a clue to the 
probable mechanism of action of these non-specific substances. 
CHAPTER VI 
swmM 
Attempts were made to induce active imimmity in female Swiss 
Webster mice against Ehrlich ascites tumor by the use of tumor cells 
treated with formalin, merthiolâte (thimerosal), phenol and ultraviolet 
irradiation as vaccine. This immonity was tested against an intraper­
itoneal challenge of 5,000 tumor cells given 2 weeks after the last 
immunizing injection. It was found that cells treated with ultraviolet 
irradiation produced maximum protection (86,8̂ ). With formalin- and 
merthiolate-treated cells, the protection obtained was 80.2$ and 63.7# 
respectively. Only weak protection (27.5̂ ) was obtained with cells 
treated with phenol. 
Non-specific immunizing effect of incomplete Freund's adjuvant 
mixture, zymosan, killed B. pertussis cells and 2. coli endotoxin was 
also studied. It was found that 9 of 10 mice that received 0,2 ml of 
the adjuvant mixture intraperitoneally were completely immune to an 
intraperitoneal challenge of 5,000 tumor cells. This protective effect 
was noticeable 7 days after the administration of the oil mixture and 
persisted for at least 15 days. With zymosan, this effect was demon­
strated within 2k hours after intraperitoneal injection of 800 pgm of 
the polysaccharide and disappeared after 6 days. Five days after an 
intraperitoneal injection of 2 billion merthiolate-killed B. pertussis 
cells, 8 of 10 mice were found to be more resistant to a transplant of 
5,000 tumor cells as compared to the mice that did not receive B, 
pertussis cells. This effect was found to be decreasing after the 5th 
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day but was still noticeable 18 days after the injection of B, pertussis 
cells, S. coli endotoxin, when given intraperitoneally in doses of 
20 pgm. Tuas found to increase slightly the resistance of mice. This 
effect became noticeable with a challenge given 2k hours before the 
endotoxin and persisted till 10 days after» However, from the results 
with E, coli endotoxin it appeared that the immunity stimulated by the 
endotoxin was expressed only by prolonging the appearance of ascites 
and survival time of the mice. Many of the mice that did not show 
any ascites on the 20th day were found to develop ascites on the 28th 
day, Freund's adjuvant on the other hand, appeared to produce complete 
protection against the challenge used since the mice did not show 
any ascites even hë days after the challenge. In mice immunized with 
zymosan and B, pertussis cells, a comparison of the results on the 
20th and 28th day appeared to indicate some degree of complete 
protection as many of these mice did not show any ascites on the 28th 
day which was the last day of observation. 
It was found that rabbit antiserum to tumor cells was able to 
neutralize in vitro the carcinogenic property of the Ehrlich ascites 
tumor cells if they were incubated in an appropriate dilution (ls80) 
at 37° C for 1 hour. It was also possible to passively immunize mice 
with 3 or more intraperitoneal injections of 0,1 ml of the antiserum, 
against a transplant of ̂ ,000 tumor cells. Absorption of this anti­
serum with tumor cells resulted in loss of both ̂  vitro and vivo 
neutralizing properties. Non-specific absorption with normal mouse 
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liver and spleen resulted in a decrease in the agglutinin titer (from 
1;1280 to 1*S12) but did not appear to affect its property to neutralize 
tumor cells either in vitro or vivo. It was also found that haating 
the antiserum at 56° C for 1 hour did not affect its agglutinating or 
neutralizing property. 
The probable mechanisms of action of these specific and non­
specific immunizing agents were discussed. 
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